Drugs / ONO-5334
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01384188 | Jun → Dec 2011 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00532337 Comparator | Oct 2007 → Jul 2010 | osteoporosis | Ono Pharma USA Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-5334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00532337 ↗ |
| Action | Inhibit | “Cathepsin K inhibition with ONO-5334 resulted in decreases in most resorption markers over 2 years” PMID 23873670 ↗ Feb 20141“Cathepsin K inhibitor” CHEMBL4802176 ↗ |
| Target | CTSK | “Cathepsin K inhibitor” CHEMBL4802176 ↗ |